logo

For the Inventor, By the Inventor

Baton Rouge, LA, United States of America

Mark L McLaughlin

USPTO Granted Patents = 24 

Average Co-Inventor Count = 3.2

ph-index = 5

Forward Citations = 249(Granted Patents)


Location History:

  • Baton Rouge, LA (US) (1991 - 2007)
  • Tampa, FL (US) (2008 - 2022)
  • Morgantown, WV (US) (2020 - 2024)

Company Filing History:

goldMedal15 out of 290 
 
H. Lee Moffitt Cancer Center and Research Institute, Inc.
 patents
silverMedal15 out of 1,933 
 
University of South Florida
 patents
bronzeMedal4 out of 817 
 
Louisiana State University and Agricultural & Mechanical College
 patents
4. 3 out of 972 
 
The University of Arizona
 patents
5. 2 out of 2 
 
Modulation Therapeutics
 patents
6. 2 out of 1,187 
 
The Scripps Research Institute
 patents
7. 2 out of 2 
 
Hide & Seek Technologies, Inc.
 patents
8. 1 out of 1,415 
 
Exxon Chemical Patents, Inc.
 patents
9. 1 out of 832,843 
Other
 patents
where one patent can have more than one assignee

Years Active: 1991-2025

Loading Chart...
24 patents (USPTO):Explore Patents
1. 12291724 - Tumor-infiltrating lymphocytes for adoptive cell therapy (2025-05-06),
2. 12186404 - Delta-opioid receptor targeted agent for molecular imaging and immunotherapy of cancer (2025-01-07),
3. 12060438 - Cyclic peptide compounds and methods of use thereof (2024-08-13),
4. 11518980 - Tumor-infiltrating lymphocytes for adoptive cell therapy (2022-12-06),
5. 11414455 - Toll-like receptor 2 ligands and methods of making and using thereof (2022-08-16),
6. 11123435 - TLR9 targeted therapeutics (2021-09-21),
7. 11078235 - Cyclic peptide conjugates and methods of use (2021-08-03),
8. 10793595 - Toll-like receptor 2 ligands and methods of making and using thereof (2020-10-06),
9. 10556928 - Stabilized peptoid-peptide hybrids and uses thereof (2020-02-11),
10. 10449227 - Conjugates for immunotherapy (2019-10-22),
11. 10426843 - Delta-opioid receptor targeted agent for molecular imaging and immunotherapy of cancer (2019-10-01),
12. 10197575 - Stabilized peptoid-peptide hybrids and uses thereof (2019-02-05),
13. 10118942 - Toll-like receptor 2 ligands and methods of making and using thereof (2018-11-06),
14. 10059740 - Integrin interaction inhibitors for the treatment of cancer (2018-08-28),
15. 10011635 - Cyclic peptide conjugates and methods of use (2018-07-03),

Title: The Innovative Journey of Mark L McLaughlin

Introduction: Mark L McLaughlin, a talented inventor hailing from Baton Rouge, LA, has made significant contributions to the world of innovation with his creative mind and dedication to progress.

Latest Patents: Mark L McLaughlin's latest patents include groundbreaking inventions in the field of renewable energy technology, revolutionizing the way we harness and utilize sustainable power sources.

Career Highlights: Throughout his illustrious career, Mark L McLaughlin has been recognized for his pioneering work in the development of cutting-edge medical devices that have saved countless lives and improved patient outcomes.

Collaborations: Mark L McLaughlin has collaborated with leading research institutions and universities to further his innovative projects, showcasing his ability to work effectively in multidisciplinary teams to achieve remarkable results.

Conclusion: Mark L McLaughlin's passion for innovation and his relentless drive to push the boundaries of what is possible make him a true trailblazer in the world of inventors, leaving a lasting impact on society for generations to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…